4/5 HEAL Consortium: Establishing Innovative Approaches for the HEALthy Brain and Child Development Study

孕妇使用阿片类药物的人数显着增加，因此增加了5倍以上 新生儿戒断综合征（NAS）的发病率自2000年以来一直有报道。初步研究 产前阿片类药物暴露与神经发育受损的风险增加有关， 认知运动和行为领域因此，严格描述产前检查影响的研究 阿片类药物暴露对早期大脑发育的影响是迫切需要的。在我们的应用程序中，五个机构（杜克 阿肯色州大学儿童研究所，辛辛那提儿童医院，伊利诺伊大学 厄巴纳-香槟和查佩尔山的北卡罗来纳州大学）具有互补的专业知识， 成立了一个联盟来制定战略，为第二阶段健康大脑和儿童发展做准备 研究，一项计划中的大规模多中心研究，旨在检查产前药物的长期影响 长期的童年结局。利用我们多学科团队的独特技能，我们将 制定必要的工具和战略（招聘/保留协议，评估电池， II期研究（目标1）的工具）。我们将进行试点研究（胎儿和产后成像，先进的 成像协调和质量控制、评估管理、生物采样），以评价仪器 II期研究（目标2）。最后，我们将分析可用的数据（目标3），包括成像，行为， 从专注于早期大脑发育的研究中获得的认知和母体数据， 指导II期研究设计。在完成了建议的目标后，我们的财团将处于一个理想的状态， 进行未来的II期研究。

Opioid use among pregnant women is increasing significantly, and consequently, a more than 5-fold increase in the incidence of neonatal abstinence syndrome (NAS) has been reported since 2000. Preliminary studies show that prenatal opioid exposure is associated with increased risk of impaired neurodevelopment across cognitive, motor and behavioral domains. Therefore, studies to rigorously characterize the impacts of prenatal opioid exposure on early brain development are critically needed. In our application, five institutions (Duke University, Arkansas Children’s Research Institute, Cincinnati Children’s Hospital, University of Illinois at Urbana-Champaign and University of North Carolina at Chapel Hill) with complementary expertise, have formed a consortium to develop strategies to prepare for the Phase II HEALthy Brain and Child Development Study, a planned large scale multi-site research study to examine the long-term impact of prenatal drug exposure on long term childhood outcomes. Leveraging the unique skills of our multidisciplinary team, we will develop essential instruments and strategies (recruitment/retention protocols, assessment batteries, and novel tools) for the Phase II study (Aim 1). We will conduct pilot studies (fetal and postnatal imaging, advanced imaging harmonization and quality control, assessment administration, biosampling) to evaluate instruments for the Phase II study (Aim 2). Finally, we will analyze available data (Aim 3), including imaging, behavioral, cognitive and maternal data from studies focusing on early brain development, to provide critical information to guide the Phase II study design. Upon completion of the proposed aims, our consortium will be in an ideal position to conduct the future Phase II study.